Atrium Therapeutics, Inc. - Common Stock (RNA)

CUSIP: 05370A108

Q1 2024 13F Holders as of 31 Mar 2024

Type / Class
Equity / Common Stock
Shares outstanding
150,858,761
Total 13F shares
89,252,994
Share change
+13,376,987
Total reported value
$2,277,667,387
Put/Call ratio
51%
Price per share
$25.52
Number of holders
156
Value change
+$376,305,703
Number of buys
85
Number of sells
71

Quarterly Holders Quick Answers

What is CUSIP 05370A108?
CUSIP 05370A108 identifies RNA - Atrium Therapeutics, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Atrium Therapeutics, Inc. - Common Stock (RNA) as of Q1 2024

As of 31 Mar 2024, Atrium Therapeutics, Inc. - Common Stock (RNA) was held by 156 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 89,252,994 shares. The largest 10 holders included FMR LLC, RTW INVESTMENTS, LP, PRICE T ROWE ASSOCIATES INC /MD/, BlackRock Inc., Avoro Capital Advisors LLC, COWEN AND COMPANY, LLC, VANGUARD GROUP INC, STATE STREET CORP, RA CAPITAL MANAGEMENT, L.P., and ADAGE CAPITAL PARTNERS GP, L.L.C.. This page lists 156 institutional shareholders reporting positions in this security for the Q1 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.